Skip to main content

Table 1 Biodistribution with 211At-A11 minibody

From: Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

Organ1 h5 h5 h (NaClO4)p value9 h9 h (NaClO4)p value23 h42 h 
Blood20.1 ± 1.89.4 ± 0.99.1 ± 0.4ns3.2 ± 0.24.4 ± 0.6**0.00901.3 ± 0.10.3 ± 0.0 
Bone marrow5.6 ± 1.0N.D.2.7 ± 0.6N.D.N.D.N.D.N.D. 
Heart6.7 ± 0.95.1 ± 0.74.4 ± 0.3ns2.3 ± 0.22.8 ± 0.5ns1.3 ± 0.20.3 ± 0.1 
Lungs11.3 ± 0.311.3 ± 2.07.3 ± 1.1*0.02846.4 ± 1.05.6 ± 0.9ns4.0 ± 0.71.2 ± 0.2 
Salivary glands5.9 ± 0.714.7 ± 4.43.0 ± 0.7**0.006713.4 ± 1.92.1 ± 0.3****<0.000115.1 ± 3.44.2 ± 1.4 
Throat10.3 ± 4.612.3 ± 3.16.0 ± 0.1*0.018710.4 ± 2.04.3 ± 0.7**0.001114.3 ± 1.88.4 ± 4.8 
Stomach7.4 ± 2.117.4 ± 6.94.4 ± 0.7*0.025115.7 ± 2.64.1 ± 1.1***0.000213.7 ± 2.52.1 ± 0.9 
Liver9.9 ± 0.65.1 ± 0.73.1 ± 0.4**0.00872.3 ± 0.31.9 ± 0.3ns1.6 ± 0.11.0 ± 0.1 
Spleen10.5 ± 1.59.7 ± 2.15.0 ± 1.2*0.01814.8 ± 0.64.4 ± 1.2ns2.7 ± 0.21.6 ± 0.3 
Kidneys9.6 ± 0.86.6 ± 1.14.8 ± 0.8ns2.8 ± 0.32.9 ± 0.6ns1.9 ± 0.30.5 ± 0.0 
Muscle0.9 ± 0.20.9 ± 0.20.8 ± 0.2ns0.5 ± 0.10.8 ± 0.5ns0.3 ± 0.00.1 ± 0.1 
Small intestine4.1 ± 1.33.7 ± 0.32.7 ± 0.2**0.00242.4 ± 0.71.7 ± 0.3ns1.7 ± 0.60.5 ± 0.2 
Large intestine2.0 ± 0.13.4 ± 0.52.1 ± 0.5*0.01531.9 ± 0.11.5 ± 0.4ns1.3 ± 0.30.3 ± 0.2 
Bladder4.3 ± 1.311.4 ± 6.36.3 ± 1.7ns7.5 ± 4.65.7 ± 3.0ns2.8 ± 1.70.8 ± 0.3 
Tumor3.0 ± 0.27.2 ± 1.75.4 ± 1.5ns5.4 ± 2.55.6 ± 1.6ns5.6 ± 1.02.1 ± 0.6 
Prostate3.6 ± 0.611.1 ± 0.95.0 ± 0.9ns4.5 ± 0.43.5 ± 1.0ns5.0 ± 2.02.1 ± 0.7 
  1. Uptake data (%IA/g ± SD) at different times after i.v. injection of 211At-A11 minibody. At 5 and 9 hpi, data is presented with and without NaClO4 pre-treatment.(n = 4) and difference between the groups, at 5 and 9 hpi respectively, analyzed using unpaired Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
  2. %IA/g Percent of injected activity per g; i.v. Intraveneous; ns Not significantly different; N.D. Not determined